Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

laboratorios syva, s.a.u., avda. párroco pablo diez, 49-57, 24010 león, Španjolska - gonadorelin - otopina za injekciju - goveda (krave, junice)

Europska Unija - hrvatski - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - cjepivo protiv kokcidioze kod pilića - Živjeti parazitski cjepiva, imunomodulatori za ptice - piletina - za aktivna imunizacija pilića od 1 dana starosti za smanjenje kliničkih manifestacija (proljeva), lezije crijeva ооцисты i izlaz, povezan s кокцидиоза uzrokovane Эймери acervulina, Эймери brunetti, Эймери maksimu, Эймери necatrix i Эймери tenella.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer, recombinant type-d pasteurella-multocida toxin - immunologicals - svinje (nazimice i krmače) - za pasivne zaštite поросятам kroz kolostrum nakon aktivne imunizacije krmača i popravak svinje za smanjenje kliničkih znakova i poraza progresivni i непрогрессивный атрофическом рините, ali i da se smanji gubitak težine povezan s Бордетеллы-bronchiseptica i pasteurella-multocida infekcije u razdoblju tova. zadatak istraživanja su pokazala da je pasivni imunitet kod prasadi traje do šest tjedana, dok u kliničkim terenska ispitivanja, blagotvoran utjecaj cijepljenja (smanjenje nosa poraza i rezultat gubitka težine) uočeni do klanja.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - imunološki za bovide - stoka (krave i junice) - za stada imunizacija zdravih krava i junica u mliječnih pasmina goveda s ponavljajući маститов problema, kako smanjiti učestalost субклинических маститов i učestalosti i težini kliničkih znakova kliničkog мастита uzrokovane zlatni staphylococcus, escherichia štapić i коагулазонегативные stafilokoki. cijela imunizacijska shema potiče imunitet od otprilike prvog dana nakon prve injekcije do približno 78 dana nakon treće injekcije (ekvivalent za 130 dana nakon poroda).

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinantni verotoxin 2e e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svinje - aktivna imunizacija praščića od 2 dana starosti kako bi se spriječila smrtnost i smanjili klinički znakovi bolesti edema (uzrokovanog verotoksinom 2e koji proizvodi e. coli) i smanjiti gubitak dnevne debljanja tijekom završnog razdoblja u lice infekcija s verotoksinom 2e proizvodnjom e. coli do klanja od 164 dana starosti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - Липотейхоевая kiselina od komponenti biofilma prianjanje стрептококков uberis, procijediti 5616 - imunološki za bovide - stoka - za aktivna imunizacija zdravih krava i junica, kako smanjiti učestalost kliničkih интрамаммарный infekcija uzrokovana streptococcus uberis, da se smanjuje broj somatskih stanica i streptococcus uberis pozitivne kvartal uzoraka mlijeka i smanjiti proizvodnju mlijeka šteta uzrokovana streptococcus uberis интрамаммарный infekcija.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - Эймери acervulina, procijediti 003, Эймери maksimu, procijediti 013, Эймери митис, procijediti 006, Эймери ргаесох, procijediti 007, Эймери tenella, procijediti 004 - Živjeti parazitski cjepiva, imunomodulatori za ptice - piletina - za aktivna imunizacija pilića od 1 dana starosti za smanjenje poraza crijeva ооцисты i izlaz, povezan s кокцидиоза uzrokovane Эймери acervulina, Эймери maksimu, Эймери митис, Эймери ргаесох i Эймери tenella i smanjiti kliničke manifestacije (proljev), povezana je s Эймери acervulina, Эймери maksima i Эймери tenella.

Europska Unija - hrvatski - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.